Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Eureka Therapeutics Inc.
Headquarters: Emeryville, CA, United States of America
Website: http://www.eurekainc.com
Year Founded: 2006
Status: Private
BioCentury | Nov 18, 2022
Product Development
Oncolytic virus combinations move beyond checkpoint inhibitors
SITC updates suggest the next wave of oncolytic viruses will be paired with bispecifics, cell therapies
BioCentury | Jul 14, 2021
Management Tracks
BeiGene’s Liang joins Tessera as president, CFO; plus Vera, Entasis, Iterion and Anticancer
Howard Liang joined gene writing company Tessera Therapeutics Inc. as president and CFO. Liang was most recently CFO and chief strategy officer at BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), leading the
BioCentury | Jul 6, 2021
Deals
Sanofi looks to emerging target for multiple myeloma
GPRC5D targeting domain from Eureka, MSKCC adds to Sanofi’s growing oncology tool kit
BioCentury | Dec 21, 2020
Translation in Brief
Reversible control of CAR expression; plus an inflammation-reducing mAb, two intranasal COVID-19 treatments and more
BioCentury’s roundup of translational news
BioCentury | Jul 23, 2020
Deals
July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG
BioCentury | Jun 19, 2020
Deals
Lyell, Pact combine T cell techs to take on solid tumors
Two T cell companies strike a deal to develop personalized, exhaustion-resistant solid tumor therapies
BioCentury | Mar 17, 2020
Product Development
Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal
Eureka is moving its TCR-mimicking antibodies forward with a new partner and new funding
BioCentury | Jan 17, 2020
Company News
Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more
BioCentury | Sep 21, 2018
Clinical News
Eureka's ET140202 leads to tumor regression in Phase I for HCC
Items per page:
1 - 10 of 31